Rapidly acting drugs introduction references

1. Gaynes, B.N., et al., What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv, 2009. 60(11): p. 1439-45.

2. Rong, C., et al., Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Int J Environ Res Public Health, 2018. 15(4).

3. Thase, M.E., New medications for treatment-resistant depression: a brief review of recent developments. CNS Spectr, 2017. 22(S1): p. 39-48.

4. Sherwood, A.M. and T.E. Prisinzano, Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens. Expert Rev Clin Pharmacol, 2018. 11(1): p. 1-3.

5. Nichols, D.E., M.W. Johnson, and C.D. Nichols, Psychedelics as Medicines: An Emerging New Paradigm. Clin Pharmacol Ther, 2017. 101(2): p. 209-219.

6. Nutt, D., et al., Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, 2007. 369(9566): p. 1047-53.